P62/SQSTM1 expression in canine mammary tumours: Evolutionary notes. (13th August 2019)

• Record Type: Journal Article
• Authors: Mariotti, Francesca; Magi, Gian Enrico; Gavazza, Alessandra; Vincenzetti, Silvia; Komissarov, Andrey; Shneider, Alex; Venanzi, Franco Maria
• Is Part Of: Veterinary and comparative oncology. Volume 17:Number 4(2019:Dec.)
• Page Start: 570
• Page End: 577
• Publication Date: 2019-08-13
• Subjects: autophagy -- dog -- gene homology -- immunohistochemistry -- mammary tumours -- p62/SQSTM1; Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12523
• Languages: English
• ISSNs: 1476-5810

Abstract

Abstract: Recent studies highlighted the role of autophagy as a cardinal regulatory system for homeostasis and cancer‐related signalling pathways. In this context, the deregulated expression of p62 – Sequestosome1 (p62/SQSTM1) – a protein acting both as an autophagy receptor and signalling hub, has been associated with tumour development and chronic inflammation. Multiple clinical studies test drugs targeting autophagy, and even more research is on the way to clinical trials. However, no comparative investigations have been carried out to identify adequate preclinical models to assess p62‐based medicine. In veterinary oncology the role of p62 in cancer‐related pathways has been largely ignored. We compared p62 sequences in multiple organisms and found that canine p62 significantly diverges from the humans and from other animals sequences. Then, we chart by immunohistochemistry the expression levels of p62 in canine mammary tumours. A total of 66 tumours and 10 non‐neoplastic mammary samples were examined. The expression of p62 was higher in normal tissue and adenomas than carcinomas, with lowest levels of p62 protein detected in high grade carcinomas. In all cases examined the tumour stroma appeared to be p62‐negative. Taken together our results would suggest that in dogs the association between p62 expression and cancer cells overturns that reported in human breast carcinoma, where p62 accumulates in malignant cells as compared to normal epithelium. Thus, at least in canine mammary tumours, p62 should be not considered a tumour‐rejection antigen for an anti‐cancer immunotherapy.